Biocia innovation is approved for commercialization by Regulatory Authorities

December 20, 2019

Biocia Inc.

Port Murray, New Jersey, USA— Biocia Inc. (Biocia) (www.BIOCIA.com), a privately-owned biotechnology company based in Port Murray, New Jersey announced their most important and latest innovation (BIOCIA-MGDPM) has been approved by Health Canada for exclusive commercialization by a Canadian-based distribution partner of Biocia. Plans are being energetically implemented to commercialize BIOCIA-MGDPM during early 2020.

BIOCIA-MGDPM is the culmination of more than 7 years of intense research and development by Team Biocia working in concert with international partners based in USA, Canada, Asia and Europe.

BIOCIA-MGDPM is a unique, state-of-the-art formulation for the treatment of dry eye conditions, including meibomian gland disease (MGD), which occur in patients with natural tears that lack a proper quantity and balance of lipid that is needed to provide extended protection and reduction of tear evaporation on corneal and conjunctival surfaces.

BIOCIA-MGDPM contains a blend of unique osmoprotectants, bioprotectants and water-binding molecules which imbibe and retain water while providing elasticity and viscosity for prolonged residence time and patient comfort.

BIOCIA-MGDPM also contains a short-chain phospholipid component that is water soluble and one that exhibits a very high water-retaining capability. In addition to its lipophilic and hydrophilic properties which support and maintain the vital lipid layer in the tear film, it helps provide tear film stabilization for prolonged comfort and protection without the use of oils commonly used in many traditional competitive MGD products currently on the market.

The Biocia Inc. and Biocia Consulting Group leadership commented: “Actually, BIOCIA-MGDPM is two products in one as a superior eye drop for daytime use but also a welcomed eye drop for night time use because it does not contain common mineral oils or other petrolatum-based ingredients.”    

Ilan Hofmann, Ph.D., Chief Scientific Officer, Biocia Inc. and Biocia Consulting Group commented: “The BIOCIA-MGDPM innovation will provide the medical community with an advancement that offers unique features and benefits including hydrophilicity for superior water retention without use of long chain aliphatic oils commonly used to retard natural evaporation, excellent rheological properties for enhanced residence time and comfort, clear and transparent without typical milky appearance observed in many competitive alternative products, minimal temporary blurring of vision, no refrigeration required, and offered  in a preservative-free delivery system.”

Biocia Inc. leadership commented: ““The success of the BIOCIA-MGDPM innovation is also very much owed to our cooperation with key international partners.  Those collaborations have been a core component of the Biocia international  footprint in ophthalmic research and development.”    

For further information, please contact:

Ilan Hofmann

Tel.: +1 (514) 685-8118 (Canada) or (980) 229-3432 (USA) |  e-mail: ilanhofmann@gmail.com

Biocia & Sam Poong Target – High Volume but Unsatisfied Global Nasal Market

March 15, 2016

Biocia Inc. (Biocia) (www.BIOCIA.com), a privately owned New Jersey-based biotechnology company based in Port Murray, New Jersey announced the execution of a CO-DEVELOPMENT & PROFIT SHARING AGREEMENT with Sam Poong Fine Chem. Co., Ltd. (Sam Poong), a Seoul-based company in South Korea. This alliance is also in collaboration with Richfield Import & Export Trade Co. Ltd. (Richfield) based in Toronto, Canada and the Biocia exclusive international distribution agent, I-MED Pharma Inc. (I-MED), based in Montreal, Canada. The co-development alliance is intended to enable Sam Poong to first commercialize Biocia’s viscoadaptive nasal formulation in South Korea for various medical symptoms and compromised conditions of the nasal cavity including excessive dryness, bleeding, discomfort associated with use of other medications or therapy and use following surgery.

The unique viscoadaptive nasal formulation from Biocia is a proprietary formulation that was innovated during a decade of research and based upon Biocia trade secrets and know how. This Biocia Technology exhibits unprecedented properties which facilitate mucociliary transport clearance of contaminated nasal mucus to maintain health and comfort. The product will be presented in a unique delivery system which addresses the concerns of the international medical community unlike most current nasal delivery systems.

Biocia Inc. and Biocia Consulting Group leadership commented: “After developing and successfully test-marketing the first prototype version of the Biocia nasal formulation on a national basis in the United States, we enhanced the original formulation with superior product ingredients and a state-of-the art delivery system. The final development of this Biocia innovation will happen in collaboration with Sam Poong for the purpose of optimizing the future introduction of this promising Biocia Technology in a large but vastly unsatisfied global market.”

Ilan Hofmann, Ph.D., President of I-MED Pharma Inc. and Chairman of the Board of Biocia Inc. commented: “A number of features will define this unique Biocia Technology when it is ready for commercialization including a sterile presentation and enhanced rheological and clinical benefits allowing for fewer required applications needed by the patient to achieve comfort and health”. Hofmann commented: “the product is intended to be also useful following trans-nasal sinus surgery to facilitate uneventful healing and faster recovery of complications due to post-operative adhesions and bleeding”.

Yeoung-Woo Choi, President of Sam Poong Fine Chem. Co., Ltd. commented: “After careful analysis of the market, we believe this Biocia Technology is dramatically superior and unique compared to other common nasal products now being sold on the market. As a global partner with Biocia, Sam Poong intends to complete the final manufacturing validations and other testing needed for submission to regulatory authorities for marketing approval.”

Jonah Tsang, Director of Richfield Import & Export Trade Co. Ltd. commented: “We must also consider other important Asian markets for the purpose of expanding the future penetration of this unique Biocia Technology. Our expectations are high considering the superior features and benefits of Biocia Technology for the nasal indication”.

For further information, please contact:

Ilan Hofmann

Tel.: +1 (514) 685-8118 (Canada) or (980) 229-3432 (USA)  |  e-mail: ilanhofmann@gmail.com

or

Yeoung-Woo Choi

Tel.: (82)-2-469 5842  |  e-mail: sfcchoi@unitel.co.kr

or

Jonah Tsang

Tel.: (1)-416-512 0211  |  e-mail: richfield@vif.com

Biocia Inc. & I-MED Pharma Inc. align with Sam Poong Fine Chem. Co., Ltd. in Korea

July 31, 2015

Biocia Inc. (Biocia), a New Jersey-based biotechnology company announced a long term distribution alliance with Sam Poong Fine Chem. Co., Ltd. (Sam Poong), a Seoul-based company in Korea through their exclusive international distribution agent, I-MED Pharma Inc. (I-MED), based in Montreal, Canada.  The alliance will enable Sam Poong to introduce and commercialize Biocia’s viscoadaptive eye drop innovations in Korea for treatment of Ocular Surface Disorder (OSD) such as dry eye disease (DED).  Current Biocia Distribution partners sell Biocia’s products in North America, Middle East, South America, Australia, Asia and Europe.

Viscoadaptive eye drops are lubricant eye drop solutions which exhibit both cohesive and dispersive behaviours depending on the shear energy exerted on the solution.  At low shear rates, the solution exhibits cohesive properties of enhanced viscosity for lubrication, protection and prevention of evaporation of the tear film.  Conversely, at higher shear rates such as the blinking process of the eyelids, it exhibits dispersive properties for enhanced elasticity allowing for optimal patient comfort and longer residence time requiring fewer applications during the day and/or night).

Biocia’s lubricant eye drops are packaged in either single-use disposable containers or preservative-free multi-use bottles.  This exclusive distribution alliance forged with Sam Poong will focus on both state-of-the-art delivery configurations.

Biocia Inc. and Biocia Consulting Group leadership commented:  “The breadth and resources of Sam Poong are intended to optimize the potential of Biocia products in this important market.  It represents the culmination of market research and product development dedicated to meet patient preference in Asia for treatment of ocular surface disorders including mild, moderate and severe dry eye syndromes.” 

Ilan Hofmann, Ph.D., President of I-MED Pharma Inc. and Chairman of the Board of Biocia Inc. commented:  “Our close relationship with Biocia enables both companies to expand their presence in growing international markets.  Korea is a significant segment of the global OSD market which is projected to be growing >13% per year.”

Yeoung-Woo Choi, President of Sam Poong Fine Chem. Co., Ltd. commented:  “We are pleased to offer the superior technology offered by Biocia’s products to our patients.  During the coming months, the management teams of Sam Poong, Biocia and I-MED will focus on submission of multiple Biocia-innovated eye drop products to KFDA for approval and launch.”

Jonah Tsang, Director of Richfield Import & Export Trade Co. Ltd. commented:  “We feel honored to coordinate the negotiations between Biocia Inc., I-MED Pharma Inc. and Sam Poong Fine Chem. Co.  We are confident the superior features and benefits of Biocia’s products will result in successful penetration of the Korean dry eye market for both therapeutic indications and post-surgical use following Lasik refractive surgery.”

For further information, please contact:

Ilan Hofmann

Tel.: +1 (514) 685-8118 (Canada) or (980) 229-3432 (USA) | e-mail: ilanhofmann@gmail.com

or

Yeoung-Woo Choi

Tel.: (82)-2-469 5842 | e-mail: sfcchoi@unitel.co.kr

or

Jonah Tsang

Tel.: (1)-416-512 0211 | e-mail: richfield@vif.com

BIOCIA INNOVATION LEADS EYEDROP MARKET in 2015

Biocia Inc., a New Jersey-based biotechnology company announced the recent commercialization of their viscoadaptive eye drop innovations in a preservative-free delivery system through key Biocia licensing partners in North America for Ocular Surface Disorder (OSD) such as dry eye disease (DED). Biocia licensing partners include Oasis Medical Inc. in the United States (Oasis Tears^® PF) and I-MED Pharma in Canada (I Drop^® PUR and I-Drop^® PUR Gel).

Viscoadaptive eye drops are lubricant eye drop solutions which exhibit both cohesive and dispersive behaviours depending on the shear energy in the solution. At low shear rates the solution exhibits cohesive behaviour (enhanced viscosity for lubrication, protection and prevention of evaporation of the tear film) and at higher shear rates it may exhibit dispersive behaviour (enhanced elasticity for optimal patient comfort and longer residence time requiring fewer applications during the day and/or night).

Lubricant eye drops are often packaged in multi-use bottles which contain preservatives. This is not the case with this preservative-free multi-use delivery system.

Biocia Inc. and Biocia Consulting Group leadership commented: “I Drop^® PUR, I Drop^® PUR Gel and Oasis Tears^® PF are the culmination of research and product development at Biocia dedicated to trends that reflect patient preference”.

Ilan Hofmann, Ph.D., President of both I-MED and Biocia commented: “this latest innovation is strengthening I-MED’s commercial presence in the Canadian OSD market which is projected to be growing >13% per year with state-of-the-art products that are superior to others commonly marketed in Canada”.

Craig Delgado, MBA, President of Oasis Medical Inc. commented: “We are pleased to have found a convenient delivery system for Oasis Tears^® that combines the benefits of preservative-free TEARS with the convenience of an easy-to-to-use multi-use bottle”.

For further information, please contact:

Ilan Hofmann

or
Denise Starbird, Oasis Medical Inc. at: 909 305 5414 e-mail: dstarbird@oasismedical.com

I-MED Approvals By Health Canada

I-MED Pharma Inc., a Montreal-based biotechnology company and Biocia Inc., a New Jersey-based biotechnology company announced today the Health Canada approval for their fourth generation preservative-free, multi-dose, viscoadaptive eye drop, I-Drop® PUR Gel for treating Ocular Surface Disorder (OSD) such as dry eye disease (DED). This product already received a CE mark earlier this year.

Read more

Biocia and I-MED Pharma Consummate a Long-Term R&D Agreement With Matrix Biology Institute

Biocia Inc. and I-MED Pharma Inc. have strengthen their foothold in global ophthalmic eye markets with an alliance with MBI to develop innovative, state-of-the art products incorportaing MBI’s patented HylaSponge® technology.

Read more